Transaction #37197 · Form 4 · 0001992352-26-000009
REGENERON PHARMACEUTICALS, INC. · Exercise / conversion · Common Stock
REGENERON PHARMACEUTICALS, INC. · Transacted October 30, 2026 · Filed November 3, 2026
What does this filing report?
An SEC Form 4 filing for REGENERON PHARMACEUTICALS, INC. records an exercise / conversion involving Common Stock on October 30, 2026. The reported quantity was 400. The filing date is November 3, 2026. This is one transaction record; amounts are not allocated among any joint reporting owners.
The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.
Transaction details
- Company CIK
- 0000872589
- Security type
- Non-derivative
- Acquisition type
- Exercise / conversion · Code M
- Quantity acquired
- 400
- Reported price
- 719.37
- Reference value
- 287,748
- Currency
- Currency not specified
- Ownership
- Direct
- Holdings after transaction
- 1,003
- Ownership description
- Not reported
- SEC acceptance time
- Nov 3, 2026, 4:22 PM EST
- 10b5-1 indication
- Indicated in filing
Reference value is reported quantity × reported price. It is not a confirmed cash payment or an estimate of a derivative's economic value. A missing currency is not assumed to be USD.
Reporting owners
- Guarini Kathryn ↗
Director
CIK 0001992352
These are the reporting owners named in the filing. Quantities and amounts are not allocated among co-reporters. Roles reflect this filing, not a current profile.
Company listings
The linked listing is identified separately from other current company listings.
Filing footnotes & remarks
- F1
- Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 13, 2026.
- F2
- On the date of the Company's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that had passed from the date of grant became exercisable, and the remainder became exercisable on the first anniversary of the date of grant.
Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.
This record was updated Eastern Time. This is the stored record update time, not the transaction date. Report a correction.